Et al Phillip Frost MD - 19 Aug 2025 Form 4 Insider Report for Fluent, Inc. (FLNT)

Role
10%+ Owner
Signature
/s/ Dr. Phillip Frost, M.D., Trustee
Issuer symbol
FLNT
Transactions as of
19 Aug 2025
Net transactions value
+$1,000,001
Form type
4
Filing time
21 Aug 2025, 17:02:52 UTC
Previous filing
19 Aug 2025
Next filing
12 Sep 2025
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
FROST PHILLIP MD ET AL 10%+ Owner 4400 BISCAYNE BLVD, MIAMI /s/ Dr. Phillip Frost, M.D., Trustee 21 Aug 2025 0000898860
Frost Gamma Investments Trust 10%+ Owner 4400 BISCAYNE BLVD, MIAMI /s/ Dr. Phillip Frost, M.D., Individually 21 Aug 2025 0001380896

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FLNT Pre-Funded Warrants Award $1,000,001 +571,429 $1.75 571,429 19 Aug 2025 Common Stock 571,429 $0.000500 Held by Frost Gamma Investments Trust F1, F2
transaction FLNT Warrants Award $0 +571,429 $0.000000 571,429 19 Aug 2025 Common Stock 571,429 $2.21 Held by Frost Gamma Investments Trust F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole stockholder of Frost-Nevada Corporation. The reporting persons disclaim beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that any reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 Each Pre-Funded Warrant is immediately exercisable for one share of the issuer's common stock, $0.0005 par value per share (the "Common Stock"), and will expire when exercised in full.
F3 Each Warrant will be exercisable for one share of Common Stock at any time on or after the date that is six months and one day following the date of issuance for a period of five and one-half years from the date of issuance. Notwithstanding the foregoing, the Warrants shall be exercisable at any time on or after the date that applicable stockholder approval is obtained and deemed effective and such Warrants shall be exercisable until the expiration date.